The Babraham Institute
The Institute is a registered charity, which receives strategic funding from the Biotechnology and Biological Sciences Research Council, UK (BBSRC). The Institute Director is Professor Michael Wakelam. BI research supports BBSRC's mission to drive advances in fundamental bioscience to underpin pharmaceuticals, health and wellbeing during ageing, and to benefit industrial wealth creation in the UK. The Institute carries out fundamental basic research into cell signalling, epigenetics and immunology with a focus on lifelong health and wellbeing and healthy ageing. Research is focused on cell signalling and genome regulation, particularly the interplay between the two, and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. From a strong base of discovery in cell signalling, internationally leading groups are studying intracellular pathways to elucidate the mechanism of action of PI3-kinases, MAP kinases, small GTPases and calcium-mediated signalling. The key proteins identified often represent targets for therapeutic intervention, providing possibilities for further, translational, research.
Role in Affinomics:
BI is responsible for overall coordination of Affinomics, including both management of financial aspects and scientific management (through Dr Taussig), carrying out the tasks as detailed in B2.1. Nonscientific management tasks include project reporting, documentation of IP, partnership tasks, internal communication, decision making and implementation, dissemination, website, access to project resources and ethical management.
Dr Taussig’s group (fomerly in partner 9, BBT) contributes high content protein arrays for binder screening and quality control (WP3,5) and manages target selection (WP8). Dr Taussig has considerable experience of managing large scale European networking and research projects having been management coordinator of the MolTools consortium (FP6), coordinator of the ProteomeBinders Research Infrastructure Coordination Action (FP6) and the AffinityProteome project directed at SMEs (FP7), and a WP coordinator in the FP7 European Biobanking and Biomolecular Resources Infrastructure (BBMRI), with responsibility for protein and antibody resources in Europe.
Dr Mike Taussig is Head of the Protein Technology Group. His experience includes structure of antibodies, protein display methods, protein array design, cell free protein expression and X-ray crystallography. He is co-inventor of ribosome display and the PISA and DAPA methods for production of protein arrays. Dr Oda Stoevesandt and Dr Ronny Schmidt are post-doctoral scientists with experience in protein array technology and optimisation who will work on both conventional protein arrays and the DAPA system.
Recent relevant publications: